Halozyme Therapeutics, Inc. $HALO Shares Acquired by Jupiter Asset Management Ltd.

Key Points

• Jupiter Asset Management nearly doubled its stake in Halozyme Therapeutics, buying an additional 768,976 shares in the fourth quarter to own 1.57 million shares valued at about $105.6 million.
• Institutional ownership remains extremely high, with hedge funds and other investors holding 97.79% of Halozyme’s stock. Several other firms also increased their positions, including Arrowstreet Capital, Dimensional Fund Advisors, and Federated Hermes.
• Halozyme reported strong quarterly results, beating EPS and revenue estimates, while analysts currently rate the stock a Moderate Buy with a consensus price target of $80.67. However, insiders have been selling shares, including CEO Helen Torley and Director Bernadette Connaughton.

Jupiter Asset Management Ltd. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 96.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,569,559 shares of the biopharmaceutical company's stock after buying an additional 768,976 shares during the period. Halozyme Therapeutics comprises approximately 0.8% of Jupiter Asset Management Ltd.'s investment portfolio, making the stock its 26th largest holding. Jupiter Asset Management Ltd. owned approximately 1.33% of Halozyme Therapeutics worth $105,631,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DLD Asset Management LP increased its stake in shares of Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company's stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company's stock valued at $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company's stock worth $152,431,000 after buying an additional 63,699 shares in the last quarter. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $124,031,000. Finally, Federated Hermes Inc. grew its stake in Halozyme Therapeutics by 294.1% during the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company's stock valued at $106,395,000 after acquiring an additional 1,082,638 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the topic of several recent research reports. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $80.67.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $53,122,698.20. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director owned 38,498 shares of the company's stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.7%

Shares of NASDAQ HALO opened at $68.18 on Friday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The business's 50 day moving average is $66.09 and its two-hundred day moving average is $68.77. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The firm has a market cap of $8.09 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 0.28 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the business earned $1.11 EPS. The company's quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.